SCHEMBL680304

SCHEMBL680304

O=[N+]([O-])c1ccc(Oc2cc3cn[nH]c3cc2Br)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
NOS1 P29475 2/20 0.53
LMNA P02545 1/20 0.53
CYP3A4 P08684 1/20 0.53
ALOX15 P16050 1/20 0.53
POLB P06746 1/20 0.53
MAOB P27338 1/20 0.53
HSPB1 P04792 5/20 0.45
AXL P30530 1/20 0.41
S1PR4 O95977 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
AMY1A P0DUB6 3/20 0.38
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
IDO1 P14902 2/20 0.36
TDO2 P48775 2/20 0.36
ROCK2 O75116 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27817110 0.86 MAPT (0.50) MAPTNOS1LMNACYP3A4ALOX15
SCHEMBL680497 0.83 MAPT (0.55) MAPTNOS1LMNACYP3A4ALOX15
SCHEMBL678942 0.82 TLR8 (0.54) MAPTNOS1LMNACYP3A4ALOX15
SCHEMBL2443701 0.82 AXL (0.48) NOS1AXL
SCHEMBL30194137 0.82 AXL (0.48) NOS1AXL
SCHEMBL2880077 0.81 MAPT (0.63) MAPTNOS1LMNACYP3A4ALOX15
SCHEMBL13288379 0.81 MAPT (0.63) MAPTNOS1LMNACYP3A4ALOX15
SCHEMBL30194080 0.80 NOS1 (0.48) NOS1MAOBAXLL3MBTL1
SCHEMBL28509646 0.80 NOS1 (0.48) NOS1MAOBAXLL3MBTL1
SCHEMBL680839 0.79 MAPT (0.45) MAPTNOS1LMNACYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
CN-102105462-A Amidophenoxyindazoles useful as inhibitors of C-MET LILLY CO ELI 2011-06-22 CN disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC MAPT 4502/4885NOS1 2168/4885LMNA 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.